17-1a. Increase the proportion of health care organizations that are monitoring and analyzing adverse events associated with medical therapies within their systems.

National Data Source	National Survey of Pharmacy Practice in Acute Care Settings, American Society of Health Systems Pharmacists.
State Data Source	Not identified.
Healthy People 2000 Objective	Not applicable.
Changes since the 2000 Publication	Revised text (see Comments).
Measure	Percent
Baseline (Year)	82 (1998)
Target	90
Target-Setting Method	Ten percent improvement. For a discussion of target-setting methods, see Part A, section 4
Numerator	Number of hospitals that track and trend adverse drug reactions.
Denominator	Number of general and children's medical surgical hospitals
Population Targeted	Pharmacy directors of general and children's medical surgical hospitals.
Questions Used To Obtain the National Baseline Data	From the 1998 National Survey of Pharmacy Practice in Acute Care Settings: ➢ *Does your hospital/system undertake the following medication-use evaluation activities?* *Tracking and trending of adverse drug reactions*
Expected Periodicity	Periodic.
Comments	An adverse event is an undesirable effect resulting from use of a medical product. This includes terms

such as adverse drug reaction (ADR), adverse experience, and adverse effect.

This objective moved from developmental to measurable during the Healthy People 2010 Midcourse Review. The original text was revised from “Health care organizations that are linked in an integrated system that monitors and reports adverse events associated with medical therapies” to “Health care organizations that are monitoring and analyzing adverse events associated with medical therapies within their systems.” The revised objective combined elements from objective 17-1 and the original text for subobjective 17-1a.

The impetus for the change was to make the objective measurable. The general intent of the reworded objective is the same as the original – to focus on linked systems monitoring and reporting adverse events.

Although the objective wording targets the extent of monitoring and analyzing adverse events related to medical therapies, the data are more accurately described as measuring these processes as they relate to medication use. It does not include the processes related to medical device use.

See Appendix A for focus area contact information.